Adding polatuzumab vedotin to bendamustine and rituximab improves survival in patients with relapsed or refractory DLBCL.
Study shows people want better preparation for transition from treatment to follow-up.
Duvelisib reports promising efficacy in people with low-grade non-Hodgkin lymphomas who have not responded to previous treatment.
Teenage and Young Adult Cancer Study published.
UK study researching impact of cancer on daily life across the UK.
Results of the Echelon-2 study show that adding brentuximab vedotin to chemotherapy improves survival in people who have CD30-positive T-cell lymphomas
The National Cohort Study researching late effects of Hodgkin lymphoma treatment will be the largest study of its kind in the world
A negative PET scan after two cycles of eBEACOPP allows treatment intensity to be reduced without affecting disease control
New trial shows a combination of ibrutinib and obinutuzumab is an alternative to ibrutinib plus chemo in first-line treatment of CLL/SLL